Proclara Biosciences Awarded Part The Cloud Grant From Alzheimer’s Association
CAMBRIDGE, MA–Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that it has been awarded a Part the Cloud grant by the Alzheimer’s Association to support the development of NPT088, Proclara’s lead candidate for the treatment of Alzheimer’s disease. Part the Cloud is an initiative that aims to accelerate research on potential new Alzheimer’s treatments by funding promising early phase drug trials in people.
The $700,000 grant will support Proclara’s ongoing Phase 1b study of NPT088 in patients with Alzheimer’s disease. NPT088 was developed using Proclara’s proprietary General Amyloid Interaction Motif (GAIM) technology, which enables the simultaneous targeting of multiple misfolded proteins. Because NPT088 targets both toxic protein aggregates implicated in Alzheimer’s disease, amyloid-β plaques and tau aggregate tangles, it may provide a superior approach to treating the complex pathophysiology of the disease over other monotherapies currently in development.
“Through the Part the Cloud program, we fund research for the disease. This grant represents the first Alzheimer’s Association grant award in New England to a biotechnology company,” said James Wessler, chief executive officer of the Alzheimer’s Association, Massachusetts/New Hampshire Chapter. “We are pleased to support Proclara in its work to develop a potentially transformative new therapy for Alzheimer’s, which affects more than five million people in the United States alone and for which there are currently no approved disease-modifying treatments.”
“We are delighted to accept this grant from the Alzheimer’s Association, which will provide us with an additional source of funding as we pursue clinical development of NPT088,” said Franz Hefti, president and chief executive officer of Proclara. “This award is a testament to the pioneering nature of our approach to treating Alzheimer’s disease, and to the great potential for NPT088 to ultimately transform care for patients suffering from this devastating disease.”